6 results about "Chronic hepatic" patented technology

The present invention relates to methods of producing hypoimmunogenic functional macrophages, and cell compositions comprising the same. The hypoimmunogenic functional macrophages may be polarised or unpolarised. Such cells may be useful in the treatment of diseases, e.g. inflammatory organ damage. The therapy that may be achieved by hypoimmunogenic functional macrophages is universal, and the cells do not require matching from donor to recipient. This broadens the application of cell-based therapies, in particular in patients with chronic liver fibrosis.

A method and oral composition for treating a plurality of end-stage diseases, such as end-stage renal disease, chronic kidney disease, liver cirrhosis, chronic liver failure, end-stage liver disease, cancer, congestive heart failure, pulmonary fibrosis, and chronic obstructive pulmonary disease, are disclosed. In one embodiment of the invention, the composition comprises testosterone duodecanoate.

This invention relates to the field of biomedical technology, and particularly to protein assemblies, predictive models, and applications for predicting the incidence of chronic liver diseases based on proteomics. This invention integrates Olink proteomics technology, machine learning algorithms, and a discovery-internal validation research strategy to successfully screen and validate a set of predictive models for chronic liver diseases containing 10 plasma protein biomarkers (VCAM1, CD48, NUDT5, MILR1, TNFSF8, DDAH1, IL17RB, NFASC, FCN2, and RTN4R). Through the cross-integration of systems biology and artificial intelligence technologies, this invention develops a new approach to full-cycle prediction from early disease screening to dynamic risk monitoring, providing an innovative solution for the precise prevention and control of chronic liver diseases.

The invention belongs to the technical field of traditional Chinese medicine preparation, and particularly relates to a liver-protecting traditional Chinese medicine composition which is prepared from the following raw material medicines in parts by weight: 10-15 parts of poria cocos, 8-12 parts of pericarpium citri reticulatae, 5-10 parts of sedum sarmentosum, 3-6 parts of schisandra chinensis, 2-5 parts of scorched hawthorn fruit, 2-5 parts of hypericum perforatum, 2-5 parts of fried medicated leaven, 4-8 parts of sweet-scented osmanthus and 2-4 parts of amomum cardamomum. According to the scheme, the serum ALT and AST levels of a carbon tetrachloride induced liver injury model mouse can be remarkably reduced, the pathological injury of liver tissue is relieved, the liver protection effect in an NAFLD mouse model is remarkable, and the preparation method has the advantages of being stable in preparation process and exact in curative effect. The traditional Chinese medicine composition is suitable for acute and chronic abnormal liver functions caused by various reasons, the formula follows the medication principle of liver diseases, liver awareness and spleen transmission and when the spleen is solid, and the liver protection effect is enhanced by adding the medicine for regulating the spleen and the stomach on the basis of the medicine for regulating the liver and adding the medicine for regulating the spleen and the stomach.

The purpose of the present invention is to achieve quantitative and reliable diagnosis of liver fibrosis. Provided is a diagnostic system for chronic fibrotic liver disease, used for diagnosing or assisting in the diagnosis of a degree of chronic liver fibrosis. A diagnostic result is obtained by means of detecting tertiary lymphoid structures in a patient's liver. The system comprises: an image forming apparatus, used for imaging a stained sample of liver tissue of a patient, to obtain a sample image; and an image analysis apparatus, used for analyzing the sample image, to obtain an analysis result of tertiary lymphoid structures in the patient's liver, and further deriving a diagnostic result based on the analysis result of the tertiary lymphoid structures.

Disclosed are methods and oral compositions for treating a variety of end-stage diseases, such as end-stage kidney disease, chronic kidney disease, cirrhosis, chronic liver failure, end-stage liver disease, cancer, congestive heart failure, pulmonary fibrosis, chronic obstructive pulmonary disease. In the embodiment of the invention, the composition comprises testosterone ester dodecanoate.